



# Cerdelga in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

RARE DISEASE · GAUCHER TYPE 1

## The clinical situation

Cerdelga (eliglustat) is an FDA-approved oral substrate-reduction therapy for adults with Gaucher disease type 1 who are CYP2D6 extensive, intermediate, or poor metabolisers, dosed 84 mg once or twice daily based on CYP2D6 genotype. Manufactured by Sanofi. Requires CYP2D6 genotyping prior to initiation, a confirmed Gaucher type 1 diagnosis, and hepatologist or metabolic-disease specialist oversight.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating metabolic/haematology specialist confirms Gaucher type 1 diagnosis and CYP2D6 genotype, and documents a written clinical rationale.
- 2 Treatment facility confirmed.** A Saudi tertiary centre (Riyadh, Jeddah, or Eastern Province) accepts the case and sets the dosing plan.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed with the Saudi Food & Drug Authority.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, booked to your initiation date.
- 5 Arrival & administration.** The facility receives the product and initiates under your specialist's care; ongoing cycles dispensed per the protocol.

### Indicative economics

**Reference US cash-pay range:** USD 26,000–30,000 per 30-day supply. CYP2D6 genotyping, SFDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Cerdelga × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/cerdelga-saudi-arabia.html](https://reservemed.com/access-guides/cerdelga-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team